ReviewNanomedicine (London, England)2025
Next-generation Nanomaterial-based phototherapeutic strategies for tumor: from NIR responsiveness to smart activation.
Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Gut-brain axis dysregulation in Parkinson's disease: Mechanisms linking microbiota to neuroinflammation and α-synuclein pathology.Journal of pharmaceutical analysis · 2026Review
- Post-translational modification signature shapes the tumor immune microenvironment and predicts clinical outcomes in melanoma.Discover oncology · 2026Article
- Development of gold nanoparticles stabilized by PLGA and PVA for application in photothermal therapy.Frontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanophototherapy has emerged as a transformative approach in precision oncology, synergistically integrating photodynamic therapy (PDT), photothermal therapy (PTT), and engineered nanomaterials to enhance treatment efficacy. Nevertheless, traditional tumor phototherapy still faces challenges such as insufficient performance of photosensitizers, poor targeting, limited depth of tissue penetration, imprecise thermal control and the complexities of the tumor tumor microenvironment(TME). Addressing these obstacles has driven the evolution of tumor phototherapy toward the development of high-performance near-infrared (NIR) nanomaterials, multimodal synergistic therapies, smart-responsive nanotherapeutic platforms, and biomimetic or biologically derived nanomaterials. This review article focuses on the key advances and representative results achieved by researchers in the above four areas, with an emphasis on analyzing their potentials and challenges in enhancing therapeutic efficacy, modulating delivery, realizing deep therapy, and promoting clinical translation, with the aim of providing new ideas for the future development of nanophototherapy and scholarly research, as well as suggesting the issues that should be paid attention to when researching.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.